Clinical trial NCT03745274: Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults
Official title: Randomised, Double-blind, Placebo-controlled, Phase I Dose- Escalation Study of Two Doses GHB04L1 in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Influenza, Avian
Lead sponsor: AVIR Green Hills Biotechnology AG
Sponsor class: INDUSTRY
First posted: 2018-11-19
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults. Subjects are randomised at a ratio of 2:1 for GHB04L1 (6.8 log10 or 7.5 log10 TCID50/dose/volunteer) or placebo.

Detailed description: GHB04L1 is intended to provide a novel treatment approach for influenza virus H5N1 infection. Based on preclinical data from ferrets that demonstrated protection against challenge with wild-type virus following treatment with various dose levels of GHB04L1, vaccination with GHB04L1 might protect humans from influenza A (H5N1) virus infection.

Due to the lack of the NS1 protein, the ΔNS1 virus replicates efficiently in interferon-deficient cells but has lost its ability to grow in normal hosts and organisms. Immunisation with ΔNS1 mutant virus can cause only an abortive replication cycle in the nasal mucosa of vaccinated individuals. This allows development of replication-deficient intranasal vaccines with genetic stability of the attenuated phenotype and without virus shedding.

Eligibility criteria: Inclusion Criteria:

* Male or female healthy volunteers, 18-50 years of age
* Seronegative for H5N1 (with antibody titres \<1:10 detected in HAI assay)
* Seronegative for H1N1 (with antibody titres ≤1:20 detected in HAI assay)
* Written informed consent to participate in this study

Exclusion Criteria:

* Acute febrile illness (\>37.0°C)
* Positive influenza immunoassay at baseline
* Signs of acute or chronic upper or lower respiratory tract illnesses (sneezing, cough, tonsillitis, otitis, etc.)
* History of severe atopy
* Influenza vaccination 2006/2007 and/or later
* Known increased tendency of nose bleeding
* Volunteers with clinically relevant abnormal paranasal anatomy
* Volunteers with clinically relevant abnormal laboratory values Females with positive urine pregnancy test prior to vaccination
* Simultaneous treatment with immunosuppressive drugs incl. corticosteroids (≥ 2 weeks) within 4 weeks prior to study medication application
* Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases
* History of leukaemia or cancer
* HIV or hepatitis B or C seropositivity
* Volunteers who had undergone rhino or sinus surgery or surgery of another traumatic injury of the nose within 30 days prior to application of study medication
* Volunteers who had received antiviral drugs, treatment with immunoglobulins or blood transfusions or an investigational drug within four weeks prior to study medication application
* Volunteers who had received anti-inflammatory drugs 2 days prior to study medication application
* Volunteers who were not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

Primary outcomes:
measure: Occurrence of adverse events
timeFrame: 8 weeks
Secondary outcomes:
measure: Viral shedding
timeFrame: 3 days
measure: Local immune response
timeFrame: 8 weeks
measure: Local cytokines response
timeFrame: 3 days
measure: Systemic influenza A virus-specific antibody response
timeFrame: 8 weeks
measure: Systemic influenza A virus-specific T-cell response
timeFrame: 8 weeks
measure: Systemic natural killer cell cytotoxicity
timeFrame: 5 weeks
measure: Systemic T-cell Granzyme B assay
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Saint Petersburg
country: Russian Federation
facility: Research Institute of Influenza, Russian Academy of Medical Sciences
Study officials:
affiliation: Research Institute of Influenza, Russian Academy of Medical Sciences
name: Oleg Kiselev, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nicolodi C, Groiss F, Kiselev O, Wolschek M, Seipelt J, Muster T. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. Vaccine. 2019 Jun 19;37(28):3722-3729. doi: 10.1016/j.vaccine.2019.05.013. Epub 2019 May 30.